When a company triples its GAAP earnings per share year-over-year while simultaneously raising its dividend by 67%, long-term investors ought to take notice — especially when the stock has spent years out of favor. RingCentral (NYSE: RNG) delivered exactly that combination in its second-quarter 2026 earnings, and the market’s reaction — an 11% single-day gain capping a new four-year stock high — suggests the turnaround thesis may finally be gaining traction with institutional investors.

The numbers are worth examining in detail. RingCentral grew Q2 2026 revenue by 5.9% year-over-year to $657 million, with subscription revenues — the predictable, recurring engine of its business — rising 5.8% to $634 million and beating the company’s own guidance of $628–$633 million. More impressive was the earnings quality: GAAP diluted EPS came in at $0.45, more than tripling the $0.14 reported in Q2 2025. Non-GAAP EPS of $1.22 grew 15% year-over-year, also topping the company’s $1.15–$1.17 guidance range. Against this backdrop, management announced a first cash dividend of $0.125 per share — a 67% increase — payable to shareholders of record by August 6, 2026. That is not the action of a management team uncertain about cash flow durability.

The strategic pivot underpinning these results is worth understanding. RingCentral is repositioning itself as an “Agentic Voice AI” platform — using its proprietary global voice network and years of accumulated customer interaction data to orchestrate AI and human agents in enterprise contact centers. This is not a pivot away from its core cloud communications moat; it is a deepening of it. Businesses that have built workflows on RingCentral’s platform face meaningful switching costs, and the AI layer creates an additional wedge that could accelerate the revenue-per-seat expansion the company needs to sustain margin growth.

Institutional behavior adds texture to the thesis. While the total number of hedge funds holding RNG dipped slightly from 27 to 25 in Q1 2026, collective conviction strengthened markedly: the remaining holders grew their combined stake by 17.7%, from $344.8 million to $406 million. Fewer funds, but larger bets — a pattern that historically aligns with early-stage institutional accumulation rather than retreat.

For long-term investors, the RingCentral story is fundamentally about earnings quality catching up to what was always a defensible business. The company operates in a $40+ billion cloud communications and contact-center market where stickiness is high and enterprise churn is slow. A 67% dividend increase at this stage of its cash flow development signals management confidence that free cash flow generation is durable, not cyclical. Investors who let the stock languish through years of heavy investment and GAAP losses may be looking at a compounding setup now — one where improving fundamentals, a new income stream, and an AI narrative all converge at a price still well below the stock’s historical highs.

When a top executive at Johnson & Johnson sells nearly half her stake — $5.8 million worth of shares — the instinct is to read it as a fire alarm. But for patient investors who look past single transactions, the more important story at J&J right now is the transformation quietly compounding beneath the surface.

J&J’s Executive Vice President of Global Corporate Affairs, Vanessa Broadhurst, sold 23,054 shares on July 20th — roughly 50% of her holdings — with the stock already up 27% year-to-date. Bulls would call it routine profit-taking at an elevated price. Bears see it as a signal from someone inside the walls. The honest answer is that insider selling at record prices is common and rarely predictive on its own. What matters more is whether the underlying business justifies the valuation.

On that front, J&J’s latest results are hard to dismiss. Total revenue rose 6.6% year-over-year, with the oncology franchise up 17.3%. Darzalex — J&J’s flagship multiple myeloma treatment — grew nearly 18% and remains the company’s largest product. Carvykti, its next-generation cell therapy, posted 49.7% growth. Tremfya, used in psoriasis and Crohn’s disease, surged 72.5%, taking meaningful share from rivals. The company has effectively replaced the revenue erosion from Stelara, its older immunology blockbuster now facing biosimilar pressure — a feat that was far from guaranteed even two years ago.

The longer transformation story is structural. J&J spun off its consumer health division in 2023, separating Tylenol and Band-Aid from the higher-margin pharmaceutical and MedTech operations. It has since further streamlined by separating its orthopedics business into DePuy Synthes. The result is a more focused, higher-growth company guiding for 6% operational sales growth in 2026, backed by a deep pipeline including the OTTAVA soft-tissue surgical robot heading toward FDA review and multiple oncology candidates across myeloma and lung cancer.

For long-term investors, the central question is valuation. J&J currently trades at a forward P/E of roughly 21–22x, approximately 10% above the healthcare sector median. The dividend yield sits near 2.2%, lower than the historical average for an income name — reflecting the growth premium the market is now assigning. That is not obviously cheap, but it is not absurd for a business growing its highest-margin segment at double digits, holding a AAA credit rating, and sitting on a pipeline of drugs in high-growth therapeutic areas. The insider sale is worth noting. The compounding machine behind it is worth watching more closely.

While semiconductor stocks were grabbing headlines with a jaw-dropping 111% surge between late March and late June of 2026, a different story was quietly unfolding in two overlooked corners of the market. Healthcare and financial stocks — both trading at steep discounts to the S&P 500 — may represent the most compelling long-term value hiding in plain sight. For patient investors, the rotation now underway in AI hardware could be the signal worth acting on.

Richard Reyle, chief investment officer at Questar Capital Partners, which oversees $1.3 billion in assets, issued a pointed warning this week: mean reversion is coming for AI chip stocks. The iShares Semiconductor ETF has already fallen 18% from its June 22 peak, yet remains up 70% for 2026. Reyle draws a sobering analogy to the mid-2000s housing bubble, noting that it wasn’t a collapse in home prices that triggered the crisis — it was merely a deceleration in the rate of price increases. “It’s always the second derivative,” he told Business Insider. The same dynamic, he argues, now threatens memory makers and data center chip stocks. Warning signs are already blinking: Meta has begun selling excess compute capacity to other firms, a potential early indicator that AI infrastructure demand is topping out. Add cheaper AI models entering the market and the threat to chip earnings becomes harder to dismiss.

The flip side of this rotation is where long-term value investors should focus their attention. The healthcare sector currently trades at a forward price-to-earnings ratio of 17.9 — a meaningful 12% discount to the S&P 500’s 20.3x multiple. Reyle is particularly bullish on pharmaceutical stocks, citing Eli Lilly specifically as having roughly 25% upside potential driven by surging global demand for GLP-1 drugs like Mounjaro and Zepbound. Healthcare also carries a historically defensive profile, holding up better when broader economic momentum softens. Meanwhile, the financial sector — anchored by major banks posting record quarterly earnings — trades at an even steeper discount of 15.6x forward earnings. JPMorgan’s aggressive nationwide expansion of wealth management branches and Morgan Stanley’s record $148 billion in new assets during Q2 2026 underscore that the earnings engine in financials is accelerating, not fading.

For long-term investors, the lesson here is durable and familiar: the loudest trades are rarely the cheapest ones. When AI hardware commands 70%-plus gains in a single year, the asymmetric opportunity almost always lies elsewhere — in the sectors left behind. Healthcare’s defensive moat, GLP-1 tailwinds, and below-market valuation combine to offer genuine compounding potential over a multi-year horizon. Banks’ wealth management buildout, record earnings, and low P/E multiples tell a similar story. Neither sector requires a market collapse to deliver solid returns — they simply need the market’s attention to drift back toward fundamentals, which, historically, it always does. The compounders that are overlooked today have a way of becoming the winners that everyone wishes they had owned.

While Wall Street obsesses over AI chips and hyperscaler capex, two of America’s most recognizable logistics companies are quietly building durable, high-margin healthcare franchises — anchored by the explosive growth in GLP-1 medications and driven by infrastructure that most competitors simply cannot replicate overnight.

The numbers are striking. UPS generated its first-ever $3 billion healthcare revenue quarter in Q1 2026, a milestone CEO Carol Tomé highlighted on the April earnings call, noting the company’s global healthcare portfolio has gained market share every single year since 2021. The company followed that with a fresh $48 million investment in temperature-controlled facilities in June. FedEx, not to be outdone, launched a dedicated life sciences organization this month and disclosed that healthcare transportation revenue reached nearly $10 billion in fiscal year 2026 — a figure that would rank it among the largest standalone healthcare logistics businesses in the world. Meanwhile, DHL Supply Chain has committed 2 billion euros ($2.25 billion) to health logistics investment through 2030, with half directed to the Americas. The underlying market driving all of this: demand for temperature-sensitive biologics is projected to compound at 8.3% annually through 2033, reaching a market value of roughly $39.1 billion, per Growth Market Reports. GLP-1 adoption alone has surged from 3% of Americans in 2024 to 11% in 2026, per a July Gallup poll — and virtually all injectable GLP-1s require refrigerated cold-chain shipping from factory to patient.

What makes this particularly interesting for long-term investors is the moat geometry. Cold-chain healthcare logistics is not a business you improvise into. It requires dedicated aircraft lift, temperature-monitored warehousing networks, regulatory compliance across multiple jurisdictions, AI-driven predictive logistics (DHL is already using machine learning to anticipate cold-chain failures before they occur), and the operational credibility that global pharma companies demand when patient lives are at the end of every delivery. C.H. Robinson recently crossed $1 billion in healthcare logistics revenue largely on the back of GLP-1 demand — but it is the established players with integrated air networks, existing warehouse infrastructure, and decade-long pharma partnerships (UPS, FedEx, DHL) who are best positioned to lock in long-term contracts as the pharmaceutical industry outsources more of its cold-chain complexity. The FDA’s explicit warning that improperly stored GLP-1 drugs should not be used creates powerful liability incentives for pharma companies to stick with proven partners rather than shop on price.

For long-term investors, the takeaway is layered. First, UPS’s struggling core parcel business — pressured by Amazon’s logistics buildout and e-commerce softness — has obscured a healthcare division that is compounding quietly and gaining share in a structurally growing market. That healthcare revenue stream deserves a premium multiple relative to the commoditized parcel segment. Second, FedEx’s decision to formalize a life sciences organization signals a strategic commitment, not a tactical experiment. Third, the GLP-1 boom is still early: only 11% of Americans use these medications today, and global rollout across Europe and Asia is barely beginning. The cold-chain logistics capacity required to serve this market will be constrained for years — C.H. Robinson’s VP noted explicitly that refrigerated supply resources are “not unlimited.” Investors willing to hold through the near-term noise in the parcel and freight markets may find that the healthcare pivot at UPS and FedEx is the compounding engine hiding in plain sight inside two deeply familiar businesses.

When Bill Ackman’s Pershing Square USA (PSUS) debuted on the New York Stock Exchange in late April, it dropped 18% on its first day of trading, falling from its $50 IPO price to close at $40.93. By any short-term measure, the launch was a flop. But for patient investors who understand what they’re actually looking at, the stumble may matter far less than the underlying track record it’s attached to.

Since 2004, Pershing Square’s flagship fund has delivered a 2,644% net return — compared to 836% for the S&P 500 over the same period. That’s not a rounding error; it’s roughly 3x the index over more than two decades of compounding, through two financial crises, a pandemic, and an ongoing war premium baked into global energy markets. Ackman’s long-stated ambition is to build something in the spirit of Warren Buffett’s Berkshire Hathaway: a publicly traded, permanent-capital vehicle that lets ordinary investors ride alongside a disciplined, concentrated portfolio manager without hedge fund fee structures. PSUS charges no performance fees — a meaningful structural difference from the traditional “2 and 20” model that extracts wealth from investors before they ever see a dollar of compounding.

The portfolio itself is worth examining. Core positions include Alphabet, Amazon, Meta, Fannie Mae, Freddie Mac, Hertz, and Uber — a mix of durable franchise businesses and turnaround situations that reflects a fundamentals-first, high-conviction philosophy. These are not momentum trades; they are multi-year theses. Ackman’s track record shows he’s willing to sit in positions for years and absorb short-term pain. His 2020 bitcoin bet and his 2022 interest rate short are examples of swings with long setup periods followed by decisive action — a temperament that aligns well with long-term investors rather than quarter-to-quarter traders.

So what does the IPO stumble mean for long-term investors? Closed-end funds frequently trade at discounts to net asset value — especially in their early days, before a track record of distributions and transparency builds institutional confidence. An 18% discount on day one is uncomfortable but not unusual in this structure. The more relevant question is whether Ackman’s investing edge — demonstrated over 21 years and multiple market cycles — will translate into a format accessible to $50 retail investors. If it does, PSUS could compound quietly for years from exactly the point when the crowd walked away. Investors who ignored Berkshire’s “boring” early years after its public listing in the 1960s learned that lesson the expensive way. History doesn’t repeat, but it does suggest that a 21-year track record at 3x the S&P deserves more than a day-one price tag to define it.

While investors pour money into semiconductors and AI data centers, Mastercard sits quietly in the background — processing the financial plumbing of the global economy without fanfare, without drama, and without ever losing material market share to any of the disruption threats that have cycled through over the past two decades. That story is worth revisiting, because right now the stock is notably cheaper than its own history suggests it should be.

Mastercard trades at roughly 27 times forward earnings as of mid-2026, compared to its five-year average closer to 35 times. That compression has happened even as the business has accelerated: Q1 2026 revenue grew 15.7% year over year, an uptick from 14.2% growth a year earlier and from roughly 10% in 2024. Full-year 2025 net revenue was up 16%. The growth engine isn’t just interchange fees — a mature, low-double-digit compounder. The real accelerant is value-added services like fraud detection, data analytics, and cybersecurity, which now represent 40% of total revenue and are growing near 20% annually. That mix shift is structurally widening margins even as revenue scales.

The competitive moat deserves attention on its own terms. Mastercard and Visa together are accepted at more than 150 million merchant locations globally, backed by over 8 billion branded cards in circulation. What makes the network effect so durable isn’t the card itself — it’s the trust infrastructure built over decades: real-time fraud decisioning, chargeback guarantees, cross-border currency conversion, and bank relationships that took generations to cultivate. Entrepreneurs have tried to route around it with Buy Now Pay Later, crypto rails, real-time bank transfers, and merchant consortia. None have meaningfully dented volumes. The moat is institutional, not merely technological.

There is one legitimate bear case that patient investors should understand: Europe. The European Central Bank is advancing a digital euro with a possible 2029 rollout, explicitly framed as a mechanism to reduce European dependence on American payment networks. International markets outside the Americas represented 57% of Mastercard’s 2025 revenue, and two-thirds of eurozone card transactions currently run on non-European payment schemes. This is a real, funded, multi-year regulatory effort — not startup vaporware. The timeline is long and implementation risk is substantial, but it is the one structural headwind worth monitoring over a ten-year holding horizon.

For long-term investors, the calculus looks compelling. You’re buying a business with 15-16% revenue growth, a widening services mix, global scale, and arguably the most durable competitive moat in financial services — at a valuation roughly 20% below its five-year average. The European digital euro risk is real but slow-moving and far from certain. Compared to the valuation premiums investors are currently paying for AI hardware plays with uncertain earnings trajectories, Mastercard offers something rare: compounding growth at a discount to intrinsic value, from a business with a 60-year track record of surviving every supposed disruption thrown at it. The payments network isn’t exciting. That’s exactly the point.

The most dangerous four words in investing, as John Templeton famously warned, are “this time it’s different.” Today’s version: “AI stocks are the only game in town.” The World Cup just delivered a timeless reminder of why long-term investors who ignore that noise tend to win.

In last week’s FIFA World Cup championship, Spain won 1-0 over Argentina — not because they were flashier or louder, but because they stayed committed to their patient, possession-based strategy for 106 minutes while the scoreboard stayed blank. The lesson maps almost perfectly onto investing. Jean-Marie Eveillard ran the First Eagle Global Fund (SGENX) and watched it return 236% from inception through March 1997 — well ahead of the MSCI World Index’s 133%. Then he looked at stretched valuations, trimmed positions, and raised cash. His “reward” was three years of gut-wrenching underperformance while the Nasdaq nearly tripled between 1997 and 2000. Assets walked out the door. His fund nearly shut down. But in the decade that followed — from March 2000 to March 2010 — the S&P 500 produced negative total returns, while First Eagle more than tripled. Eveillard’s famous line: “I would rather lose half of our shareholders than half of our shareholders’ money.”

Seth Klarman’s Baupost Fund echoed the same dynamic, compounding at 15.9% annually during the “lost decade” of 1998 to 2008, while the S&P 500 lost 1.4% per year. Klarman’s prescription: “You must ignore the market and go against the grain in the short term to win in the long term.” Today, that means looking past the AI mania that has narrowed market leadership to a handful of names. Since October 2025, the Magnificent Seven stocks have advanced just 5.9% on average — while a basket of so-called “AI Survivor” stocks (companies with durable franchises entirely outside the AI arms race) gained an average of 43%. Non-AI compounders — businesses with defensible moats, consistent cash flows, and reasonable valuations — are quietly delivering returns that make FOMO-driven AI speculation look thin by comparison.

For long-term investors, the key takeaway is structural: markets routinely delay rewarding sound decisions, but that delay doesn’t invalidate them. The uncomfortable period — when discipline looks like stubbornness and patience looks like missed opportunity — is precisely where the real edge is earned. Investors who stayed committed to fundamentals while the Nasdaq soared in 1999 didn’t look smart for three years. Then they looked very smart for the next decade. The scoreboard eventually reflects the underlying quality of the game being played.

Wall Street’s attention has been laser-focused on AI hardware — Nvidia, data center REITs, the hyperscalers themselves. But Goldman Sachs just quietly pointed long-term investors toward a more overlooked corner of the energy infrastructure world: midstream natural gas companies that are powering data centers from behind the meter, and paying dividends that crush the S&P 500’s current 1.04% yield while they do it.

Goldman’s latest “Ten Buys” list of energy and power stocks names Kodiak Gas Services (KGS) and The Williams Companies (WMB) as the standout plays in its data center and power growth theme. Kodiak, a Texas-based natural gas compression specialist, is expanding rapidly into behind-the-meter power generation — supplying electricity directly to data centers without running through the local grid. Goldman sees roughly 15% EBITDA growth through 2030, driven by that expansion. The stock has already climbed nearly 75% year to date, yet Goldman’s $89 price target still implies more than 36% additional upside from recent levels. All 15 analysts covering the stock rate it a buy or strong buy, per LSEG. The dividend yield stands at 3% — nearly three times the S&P 500’s payout.

Williams Companies, meanwhile, operates one of the country’s most critical natural gas pipeline networks and is quietly diversifying into the same behind-the-meter opportunity. In May, Williams announced three new AI-era infrastructure projects: Neo, a behind-the-meter agreement with a major hyperscaler; Atlas, a gas infrastructure deal to serve a large investment-grade data center in the Northeast; and Silver Spur, an expansion of its Northwest Pipeline system. Goldman’s $82 price target suggests roughly 12% additional upside, with 20 of 25 covering analysts calling the stock a buy or strong buy. The dividend yield: 2.8%. Shares are up 24% year to date. The broader Goldman energy list also includes ConocoPhillips yielding 2.8%, Marathon Petroleum at 1.3%, and Expro Group at 1.9%.

For long-term investors, the real insight here isn’t a trade — it’s a structural shift. Natural gas infrastructure companies have historically been valued as slow-growth, income-generating pipelines. The AI buildout is repricing that thesis. Behind-the-meter power generation creates a new, high-margin revenue stream for midstream operators who already own the pipes and the compression equipment. That’s compounding on top of compounding: existing pipeline cash flows fund dividends while new data center contracts layer in incremental EBITDA growth. Goldman’s conviction that “the market continues to underestimate the number of future behind-the-meter wins” for Williams in particular echoes a classic pattern — a durable moat getting a new growth driver that most investors haven’t fully priced in. Patient investors who can hold through the AI noise and focus on the underlying cash flows may find these energy infrastructure names among the more durable compounders of the current decade.

When a business that has quietly compounded shareholder wealth for over two decades suddenly trades at the cheapest valuation since the Global Financial Crisis, long-term investors ought to pay attention. That is the situation today with Intercontinental Exchange (NYSE: ICE), the operator of some of the world’s most critical financial market infrastructure — exchanges, clearing houses, mortgage technology, and proprietary data networks that financial institutions, corporations, and governments depend on daily.

As of July 17, 2026, ICE traded at $139.65 per share, implying a forward price-to-earnings ratio of roughly 17x — a level not seen since 2008-2009. For context, ICE posted record Q1 2026 net revenues of $3 billion, up 20% year-over-year, demonstrating that the business continues to grow even as its stock has shed nearly 23% over the past 52 weeks. The disconnect between operational strength and market price is striking. Eighty-six hedge fund portfolios held ICE at the end of Q1 2026, up from 83 the prior quarter, suggesting that sophisticated long-term capital is quietly accumulating the stock even as retail sentiment has cooled.

The market’s concerns center on two issues: first, that AI could erode demand for ICE’s proprietary data and analytics products; second, that the Commodity Futures Trading Commission may authorize new “perpetual” derivatives and expand crypto competition, threatening ICE’s regulated exchange business. Both risks deserve scrutiny, but long-term investors should weigh them against ICE’s structural advantages. The company operates essential infrastructure across energy futures, interest rate derivatives, equity options, and the dominant U.S. mortgage origination platform (Encompass, through its Black Knight acquisition). These are not businesses that customers easily abandon — switching costs are enormous, regulatory relationships are deep, and network effects strengthen over time. The data and analytics concern in particular looks more peripheral than existential: financial institutions using ICE’s fixed-income pricing, risk analytics, and exchange connectivity have few credible alternatives at scale.

For long-term investors, the key question is not whether ICE faces headwinds — every business does — but whether those headwinds justify a valuation not seen since one of the worst financial crises in modern history. ICE emerged from 2008-2009 significantly stronger, capturing clearing mandates that reshaped derivatives markets globally. A company with record revenues, 20% top-line growth, expanding hedge fund ownership, and durable moats in financial infrastructure trading at 17x forward earnings deserves a hard look from any patient, fundamentals-oriented investor. The market appears to be pricing in permanent impairment; the underlying business is printing record results.

For decades, Warren Buffett’s reluctance to invest in technology companies was one of the most reliable patterns in professional investing. He missed Google in the early 2000s, famously admitting Berkshire Hathaway’s GEICO subsidiary had been buying advertising from the company all along — yet he never pulled the trigger on the stock. That self-described “mistake” has now been corrected in the most decisive way imaginable: Berkshire Hathaway has quietly built a $30 billion position in Alphabet, and Buffett himself has confirmed he personally initiated every dollar of it.

The disclosure came during a July 18 interview on CNBC, where Buffett surprised observers by clarifying that the Alphabet investment — which many had attributed to new Berkshire CEO Greg Abel — was his own call from the start. The stake was assembled in three distinct moves: roughly $4.3 billion purchased in the third quarter of 2025, a further $11.5 billion added in the first quarter of 2026, and then an additional $10 billion acquired by purchasing shares directly from Alphabet as part of the tech giant’s broader AI infrastructure funding plan. That structure alone is noteworthy — Berkshire is not just buying in the open market; it is providing capital directly to one of the world’s most dominant businesses. Buffett’s own characterization of Alphabet is telling: he believes the company is “more likely to be a winner, based on their record, than probably 90 to 95 percent of what gets merchandised through Wall Street.” That is an extraordinary endorsement from a man who built his career avoiding exactly this kind of bet.

The long-term implications for patient investors go well beyond Alphabet itself. First, Buffett’s willingness to invest $30 billion in a company he openly says spends “huge amounts of money” on AI infrastructure — despite having reservations about AI capex broadly — signals something important about competitive moats in the modern economy. Google Search, YouTube, Google Cloud, and Android together represent a rare collection of durable, high-margin franchises that compound quietly regardless of which AI model wins the hype cycle. Second, Berkshire simultaneously appears to be buying back $5 to $11 billion of its own shares in the second quarter, according to Barron’s estimates — a signal that Buffett sees Berkshire itself as undervalued even as he deploys capital aggressively into equities. Third, Apple remains Berkshire’s largest equity holding at $76 billion. For long-term investors watching where Buffett is putting the world’s largest non-sovereign investment portfolio, the message is consistent: patient capital flows toward businesses with structural advantages, pricing power, and the scale to absorb uncertainty — not toward whatever narrative Wall Street is selling this quarter. The Alphabet move is less a tech bet than a moat bet. That distinction matters enormously over a decade-long time horizon.